Clinical trials: Diabetes Mellitus Type 2 (T2DM)
Type 2 Diabetes Mellitus (T2DM), Overweight , Obesity
A Study to Evaluate Different Administration Conditions and the Food Effect of MWN109 Tablets in Chinese Participants
This is a randomized, open-label, multiple-dose study to evaluate the effects of different volumes of administration water, post-dose fasting duration, and high-fat diet on the pharmacokinetics of the 15 mg dose of MWN109 tablets…
- Trial name
- NCT07801326
- Testing
- MWN109 Tablets
- Where
- China
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Type 2 Diabetes Mellitus (T2DM), Pain
Effects of Self-Selected Music on Self-Injection Fear, Blood Glucose Testing Fear, and Pain
Fear and pain associated with self-insulin injection and blood glucose self-testing may negatively affect diabetes self-management.
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Pain, Fear of Injections
- Trial name
- NCT06790550
- Testing
- Self-Selected Music Listening
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Dicle University
Type 2 Diabetes Mellitus (T2DM)
A Study of an Existing Database to Assess the Treatment Persistence to Basal Insulin in Type 2 Diabetes Mellitus Patients in a Structured Patient Education Program in India
The aim of this study is to analyze data from an existing database named SAATH-7 Star, in order to assess the treatment persistence to basal insulin in Type 2 diabetes patients who had been enrolled in the SAATH-7 Star structured…
- Trial name
- PERSISTENT (NCT05628090)
- Where
- France
- Volunteers
- 47,885 people
- Sponsor
- Sanofi
Type 2 Diabetes
Hybrid Closed-Loop for Perioperative Glycemic Control in T2DM With Parenteral Nutrition
Glycemic control in surgical patients with type 2 diabetes mellitus (T2DM) receiving parenteral nutrition represents a major clinical challenge.
- Trial name
- NCT07121504
- Testing
- Hybrid closed-loop insulin delivery system, conventional insulin pumps combined with CGM
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Xiangya Hospital of Central South University
T2DM
Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin
Phase 3 study to assess the Efficacy and Safety of CT-L03-301 in Type 2 Diabetes Patients with Insufficient Glycemic Control with Metformin and Empagliflozin Combination Therapy.
- Trial name
- CT-L03 (NCT06571591)
- Testing
- CT-L03 Group 1, CT-L03 Group 2, Empagliflozin
- Where
- South Korea
- Volunteers
- 606 people
- Sponsor
- Celltrion
Food Insecurity, Type 2 Diabetes Mellitus (T2DM)
Food Insecurity, Social Determinants of Health
Food is Medicine for the whole will test an intervention which provides medically tailored meals, or grocery voucher cards, or a combination of these food and nutrition resources to a caregiver and children living in the…
- Conditions
- Food Insecurity, Type 2 Diabetes Mellitus (T2DM), Hypertension
- Trial name
- NCT06784310
- Testing
- Medically Tailored Meals, Grocery Prescription, Medically Tailored Meals and Grocery Prescription
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Alison Gustafson
MASLD, T2DM (Type 2 Diabetes Mellitus)
Non-Invasive MASLD Diagnosis & T2D Remission Biomarkers
The goal of this observational study is to prospectively develop and validate a non-invasive scoring system based on metabolic markers, proteomic, and transcriptomic profiles to accurately screen, diagnose, stage, and monitor…
- Conditions
- MASLD, T2DM (Type 2 Diabetes Mellitus), Non-alcoholic Fatty Liver Disease (NAFLD), Obesity
- Trial name
- ENSURE-MASLD (NCT07172997)
- Testing
- Bariatric Surgery
- Where
- 2 sites in Bahrain
- Volunteers
- 163 people
- Sponsor
- Royal College of Surgeons in Ireland - Medical University of Bahrain
NASH, NASH - Nonalcoholic Steatohepatitis
Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH
A randomized, multi-center study evaluating MET409 (50 mg) alone or in combination with empagliflozin (10 mg) for 12 weeks. Assignment to MET409 will be double-blind and placebo-controlled.
- Conditions
- NASH, NASH - Nonalcoholic Steatohepatitis, Type 2 Diabetes, Diabetes Type 2
- Trial name
- NCT04702490
- Testing
- MET409 Active, Empagliflozin
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- Metacrine, Inc.
Diabetes Mellitus, Type 2
A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Participants
The purpose of the study is to investigate the cardiovascular disease (CVD) risk profile among participants newly diagnosed with type 2 diabetes mellitus (T2DM) in Southeast Asia (CRISTAL SEA).
- Trial name
- CRISTALSEA (NCT07532863)
- Testing
- No treatment given
- Where
- 6 sites in Indonesia, Malaysia and 2 more
- Volunteers
- 400 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes, Insulin Resistance
Characteristics of Papez Loop Neural Network in T2DM （Type 2 Diabetes Mellitus）
This is a cross-sectional and longitudinal study to investigate the characteristic changes in Papez's circuit neural network activity and connectivity based on multimodal MRI, and through follow-up study of the interaction…
- Conditions
- Type 2 Diabetes, Insulin Resistance, Cognitive Impairment
- Trial name
- T2DM (NCT06912321)
- Testing
- No Intervention: Observational Cohort
- Where
- China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Type 2 Diabetes (T2DM)
Remission Evaluation of Metabolic Interventions in Type 2 Diabetes in Primary Care (REMIT-Prime)
The Remission Evaluation of Metabolic Interventions in Type 2 diabetes (REMIT) program incorporates a non-surgical-remission-inducing therapeutic approach, pairing health coaching with physician-led pharmacotherapy.
- Trial name
- REMIT-Prime (NCT07665567)
- Where
- Canada
- Volunteers
- 118 people
- Sponsor
- McMaster University
Coronary Artery Disease, Type 2 Diabetes
Empagliflozin Versus Vildagliptin in CAD Patients With T2DM
We compared the cardioprotective effects of empagliflozin, an SGLT2 inhibitor, with those of vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, focusing on various inflammatory biomarkers lipid profile, and cardiac…
- Trial name
- NCT06313008
- Testing
- Empagliflozin 10 MG, Vildagliptin 50 MG
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- Damanhour University
Type 2 Diabetes Mellitus (T2DM)
Glycemic Variability of Combination Therapies in T2DM
Glycemic Variability of Combination Therapies in T2DM
- Trial name
- NCT07442006
- Testing
- Empagliflozin/Metformin, Anagliptin, Metformin
- Where
- South Korea
- Volunteers
- 178 people
- Sponsor
- JW Pharmaceutical
Type 2 Diabetes Mellitus (T2DM)
the Effect of Fasted Versus Post-meal HIIT on Glycemic Control in Men With Type 2 Diabetes Mellitus
Background: Recently, high intensity interval training (HIIT) has emerged as a promising regimen for the management of type 2 diabetic subjects.
- Trial name
- HIIT (NCT06659848)
- Testing
- high intensity interval training
- Where
- Saudi Arabia
- Volunteers
- 123 people
- Sponsor
- Prince Sattam Bin Abdulaziz University
T2DM
Efficacy and Safety of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion in Uncontrolled Type 2 Diabetes
The randomized, controlled clinical trial investigate the efficacy and safety of vildagliptin added to continuous subcutaneous insulin infusion in uncontrolled type 2 diabetes
- Trial name
- NCT03563794
- Testing
- CSII+Vildagliptin, CSII(insulin Lispro)
- Where
- China
- Volunteers
- 400 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Type 2 Diabetes Mellitus
A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes
The main purpose of this study is to evaluate the safety and efficacy of once weekly dulaglutide when added to insulin glargine, with metformin and/or acarbose in Chinese participants with type 2 diabetes mellitus.
- Trial name
- AWARD-CHN3 (NCT04591626)
- Testing
- Dulaglutide, Insulin Glargine
- Where
- 27 sites in China
- Volunteers
- 291 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus (T2DM)
Phase III Trial of SGLT2 Inhibitor and Thiazolidinedione Fixed-Dose Combination vs. Monotherapy in Type 2 Diabetes Patients on Metformin
This clinical trial is studying whether combining two commonly used diabetes medications into a single pill works better than taking them separately for people with type 2 diabetes who are already on metformin.
- Trial name
- CONTROL (NCT07057479)
- Testing
- Fixed-dose combination of SGLT2 inhibitor and thiazolidinedione, Control Group 1 Intervention - SGLT2 inhibitor monotherapy, Control Group 2 Intervention - Thiazolidinedione monotherapy
- Where
- Brazil
- Sponsor
- Eurofarma Laboratorios S.A.
Diabetic Retinopathy, Type 2 Diabetes Mellitus
The Relationship Between Advanced Glycation Endproducts and Diabetes
The overall purpose of this COMIRB application is to perform a cross-sectional pilot study to aid in the design of a prospective epidemiologic study for an NIH grant application.
- Trial name
- NCT02662010
- Where
- United States
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Type 2 Diabetes, Physical Exercise
The Use of Short SMS Messaging With Type 2 Diabetes (T2DM)
Physical activity (PA) can play a vital and an independent role in type 2 diabetes (T2DM) management care. Health research studies have shown evidence that PA can improve glycaemic control and glucose levels.
- Trial name
- mHealth (NCT04243174)
- Testing
- SMS Messaging
- Where
- Saudi Arabia
- Volunteers
- 57 people
- Sponsor
- University of Nottingham
Type 2 Diabetes Mellitus
A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)
The purpose of this study is to assess the efficacy and safety of sitagliptin/simvastatin fixed-dose combination (FDC) in participants with T2DM who have inadequate glycemic control while on metformin monotherapy.
- Trial name
- NCT01678820
- Testing
- Sitagliptin/Simvastatin FDC, Sitagliptin, Simvastatin
- Volunteers
- 299 people
- Sponsor
- Merck Sharp & Dohme LLC